Clinical Trials Logo
  1. Home
  2. Colitis
  3. NCT02768038
  4. Details
NCT02768038 Clinical Trial

Intestinal Microbiome and Chronic Inflammatory Bowel Disease

Colitis Clinical Trial

Official title:
The Role of Intestinal Microbiome ih the Pathogenesis and Course of Chronic Inflammatory Bowel Diseases

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02768038
Other study ID # TurkuUH2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2016
Est. completion date December 2020

Study information
Verified date June 2019
Source Turku University Hospital
Contact Mervi Tenhami, MD
Phone +35823130000
Email marvi.tenhami@tyks.fi
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim is to examine the role of intestinal microbiota in the pathogenesis of chronic inflammatory bowel diseases (IBD)

Description:

IBD patients to whom colonoscopy is performed will be recruited. Mucosal specimens from large intestine and terminal ileum will be collected as well as stool specimens. The microbiota will be analyzed at the microbiology laboratory and the results will be correlated with endoscopical, laboratory and histopathological findings.

Recruitment information / eligibility
Status Recruiting
Enrollment 120
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- IBD

Exclusion Criteria:

- patient refusal to participate

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Observational
Blood, stool ja biopsy specimens

Locations
Country Name City State
Finland Turku University Hospital Turku

Sponsors (1)
Lead Sponsor Collaborator
Turku University Hospital

Country where clinical trial is conducted

Finland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change of microbiome in chronic inflammatory bowel disease 5 yrs
See also
  Status Clinical Trial Phase
Completed NCT00272818 - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Completed NCT01369355 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Phase 3
Completed NCT02709213 - Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
Completed NCT00533078 - Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies Phase 2
Terminated NCT00184171 - Treatment of Microscopic Colitis N/A
Recruiting NCT05333978 - Optoacoustic Detection of Inflammation Using MSOT Device N/A
Not yet recruiting NCT06424769 - Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management N/A
Recruiting NCT04272307 - MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
Completed NCT05514561 - FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
Completed NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease Phase 2
Recruiting NCT02687724 - Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis Phase 4
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01326013 - A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel Phase 2
Not yet recruiting NCT05726396 - A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis Phase 2
Completed NCT05414552 - ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Recruiting NCT04407247 - Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Phase 1/Phase 2
Completed NCT01369329 - A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Phase 3
Completed NCT01369342 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) Phase 3
Terminated NCT00936585 - NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease N/A
Completed NCT06074874 - Intestinal Biomarker Analysis After ECP for ICI Colitis